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Abstract 
Purpose: To optimize and characterize amoxicillin encapsulated in mucoadhesive alginate-coated 
chitosan microparticles for the treatment of gastric and duodenal ulcers caused by Helicobacter pylori. 
Methods: Eighteen batches of various ratios of chitosan, sodium alginate and calcium chloride were 
prepared by ionotropic gelation method. The batches were optimized based on their particle size (PS) 
and drug encapsulation efficiency (PDEE). Optimized batches were further evaluated for in vitro drug 
release, bacterial susceptibility and mucoadhesion. 
Results: Microparticle size ranged from 0.70 ± 0.37 to 5.25 ± 0.70 µm. Drug encapsulation efficiency 
ranged from 95.79 to 97.42 % while maximum drug released after 24 h was 44.79 % in simulated 
gastric fluid (SGF). Mucoadhesion reached a maximum of 76 % in simulated intestinal fluid (SIF). Drug 
release followed Higuchi model of release kinetics while the release exponent, n, was > 0.9 in all the 
formulations. There was a significant difference between the inhibition zone diameter (IZD) of the 
optimized formulations and that of a commercial brand of amoxicillin when they were tested against 
Salmonella typhi and Staphylococcus aureus. 
Conclusion: The mucoadhesive amoxicillin microparticles may improve the treatment of gastric ulcer 
caused by H. pylori due to enhanced adhesion of the formulation to the pig’s ileum and the increased 
antibacterial property against Salmonella typhi and Staphylococcus aureus. 
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Amoxicillin, a semi-synthetic, orally absorbed, 
broad-spectrum antibiotic is still commonly used 
in the treatment of gastric and duodenal ulcers 
caused by H. pylori. One reason for incomplete 
eradication of H. pylori  is probably the short 
residence time of amoxicillin in the 
gastrointestinal tract so that effective 
antimicrobial concentration cannot be achieved 
in the gastric mucous layer or epithelial cell 
surfaces where H. pylori resides. Another reason 
may be the degradation of amoxicillin in the 
harsh stomach environment [1]. 
 
Polymeric drug carriers have played an integral 
role in the advancement of drug delivery 
technology offering three major advantages in 
delivery which are sustained release, targeted 
delivery and stabilization of the drug [2]. 
Preferably, the carrier for oral delivery should be 
mucoadhesive, biodegradable, biocompatible 
and non-toxic. A suitable approach would be a 
local application of the drug on to the gastric 
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mucosal layer with a concept of mucoadhesion 
that can adhere on to the bacterium, thus 
eliminating it completely [3]. Chitosan, the 
polymer of choice in this research is a linear 
heteropolymer of N-acetyl-D-glucosamine linked 
by β-(1-4) glycosidic bonds. It is non-toxic, 
biodegradable, biocompatible and 
mucoadhesive. Therefore, chitosan 
microparticles and their derivatives have been 
applied in biomedical field such as antibacterial 
agents, gene delivery vectors, carriers for 
release of protein and drugs [4]. Also, the 
combination of chitosan and amoxicillin may be 
synergistic as chitosan exhibits antimicrobial 
activity [3]. Chitosan microparticles can be 
formed by a variety of methods including 
emulsion, ionotropic gelation or reverse micellar 
methods. The method used here is ionotropic 
gelation method [5].  
 
Sodium alginate is also a hydrophilic polymer 
and comprises D-mannuronic (M) and L-
guluronic acid (G) residues joined linearly by 1,4-
glycosidic linkages [6]. Alginate-coated chitosan 
microparticles protects acid-labile drugs better 
from degradation in acidic solution (pH 1.5) than 
the chitosan microparticles alone. The coating 
also acts as a barrier from microbial 
contamination [7].  This research seeks to 
optimize and characterize amoxicillin 
encapsulated in mucoadhesive alginate-coated 
chitosan microparticles for the treatment of 
gastric and duodenal ulcers. The alginate coat 
prolongs contact with the intestinal mucosa and 






The following materials were used as procured 
without further purification: sodium alginate, low 
molecular weight chitosan, calcium chloride, 
acetic acid, Tween® 80 and sodium sulphate 
(Sigma Aldrich Co., Germany), distilled water 
and deionized water (National Commission for 
Energy Research and Development, University 
of Nigeria, Nsukka), amoxicillin (donation from 
Juhel Pharmaceutical Company, Emene, 
Enugu). 
 
Preparation of microparticles 
 
Alginate/chitosan microparticles were prepared in 
a two-step procedure based on ionotropic 
gelation method. A pre-gelation of polyanionic 
alginate with calcium chloride followed by 
dropwise addition of polycationic chitosan cross-
linked by sodium sulphate was prepared. Thus in 
details, a volume of 5 mL of 2 % w/v chitosan 
containing 250 mg of amoxicillin was cross-linked 
with 3.5 ml of 10 % sodium sulphate at a rate of 
1ml/min under mild agitation (< 50 rpm) and 
continuous sonication (Ultra turrax homogenizer, 
Silverson, U.K) for 15 min (room temperature, pH 
of 4.7) for the microparticle formation. Thereafter, 
1 ml of 0.55 mM calcium chloride solution was 
dropped for 30 min under 50 rpm in a beaker 
containing 5 mL of 2 % w/v sodium alginate 
solution.  The chitosan microparticles were 
dropped slowly, using a 23-gauge needle, into 
the alginate solution to achieve alginate coating 
of the chitosan microparticles. The coated 
microparticles in suspension were centrifuged at 





Stock solutions of chitosan, sodium alginate and 
calcium chloride were prepared. The ratios are 
shown in Table 1. 
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Particle size (PS) µm < 1.5 
Encapsulation 
efficiency (EE) 
% > 90 
 
Particle size determination 
 
The residue of the centrifuged sample was 
washed twice with distilled water and used for 
the particle size determination. A thin smear was 
made on a glass slide and viewed with Hund® 
binocular microscope (Helmut Hund GmbH, 
Weltzlar, Germany) attached to a Motic image 
analyser (Moticam, Xiamen, China) at a 
magnification of  x40. Three different fields of 
view were captured for each sample and the 
average taken. 
 
Percent drug encapsulation efficiency (PDEE) 
 
For quantitative determination of amoxicillin 
loading, samples were centrifuged and then the 
absorbance of the solutions in the tubes was 
measured at 267.5 nm wavelength using a 
UV/VIS spectrophotometer ((Spectrumlab 752S, 
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USA). The amount of amoxicillin associated with 
the microparticles was calculated indirectly by 
the difference between the initial amount of 
amoxicillin added to the chitosan and the amount 
measured in the supernatant. Eq 1 was used to 
determine drug encapsulation efficiency (PDEE). 
 
PDEE (%) = {(At – As)/At}100 ……………….. (1) 
 
where At and As are the total amount of 





The optimization process was done using the 
constraints imposed by the investigator seen in 
Table 1. Three optimal runs based on the 




The mucus surface of a freshly excised pig’s 
ileum was rinsed with normal saline. The tissue 
was pinned to a polythene support on a wooden 
board inclined at an angle of 60o with the aid of 
board pins and a beaker was placed under the 
base of the inclined plane to collect the 
microparticles as they get detached from the 
tissue. A 500 mg weight of the microparticles 
was placed on the trough of the mucus surface 
and allowed to hydrate for 15 min. A 100 ml of 
SIF was allowed to flow over the tissue at the 
rate of 40 drops/min. The wet microparticles 
detached was blotted dry with a filter paper and 
weighed. The weight of the microparticles 
calculated as a percentage of the original weight 
was used as a measure of mucoadhesion. The 
experiment was repeated using SGF. 
 
In vitro release studies 
 
The dissolution medium consisted of 250 mL of 
freshly prepared SGF and SIF maintained at 37 ± 
1 oC using a heater/magnetic stirrer. The 
polycarbonate dialysis membrane used was pre-
treated by soaking it in the dissolution media for 
24 h. For the study, 0.5 g of the formulated 
alginate-coated chitosan microparticles was 
placed in the dialysis membrane containing 5 mL 
of each of the dissolution medium, securely tied 
to a thermo-resistant thread and then immersed 
in the dissolution medium under agitation 
provided by the magnetic stirrer at 100 rpm. At 
predetermined time intervals, 5 mL portions of 
the dissolution medium were withdrawn, filtered 
and analysed spectrophotometrically (UV/VIS 
spectrophotometer (Spectrumlab 752S)) at 267.5 
nm. For each sample withdrawn, an equivalent 
volume (5 mL) of phosphate buffer maintained at 
the same temperature was added to the contents 
of the dissolution medium to maintain sink 
conditions throughout the release period. The 
amount of drug released at each time interval 
was determined with reference to the standard 
Beer’s plot for amoxicillin in phosphate buffer [8]. 
 
Kinetic analysis of drug release  
 
The in vitro drug release kinetic data were tested 
with the following mathematical models; zero-
order equation, first-order equation, Higuchi 
square-root equation and Korsmeyer-Peppas 
model to find the equation with the best fit. 
 
Susceptibility studies on clinical isolates  
 
Molten nutrient agar (15 mL) was inoculated with 
0.1 ml of Escherichia coli broth culture. It was 
mixed thoroughly, poured into Petri dishes and 
rotated to ensure even distribution of the 
organism. The agar plates were allowed to set 
and a sterile cork-borer (5 mm diameter) was 
used to cut three cups in the agar medium plate. 
The three different optimized microparticles were 
prepared and used as follows: 3 drops each of 
the optimized formulations were added into the 
different holes in each of the plates using sterile 
Pasteur pipettes. The plates were allowed to 
stand at room temperature for 15 min to enable 
the samples diffuse into the medium before 
incubating at 37 °C for 24 h. The inhibition zone 
diameters were carefully measured and 
recorded. The procedure above was repeated for 





The results of the susceptibility test were 
expressed as mean ± standard deviation (SD), 
and were analyzed by Students t-test using 
Microsoft Excel 2010 was used. P < 0.05 was 






The technique used for the preparation of the 
microparticles was ionotropic gelation. The 
photomicrographs of the vesicles were spherical 
and polydisperse with sizes ranging from 0.70 ± 
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Particle size (µm) Encapsulation 
efficiency (%) 
5 5 1.0 5.25 ± 0.70 97.02 
5 2.5 1.8 3.26 ± 0.92 96.39 
7.5 5 0.55 1.1 ± 0.62 96.29 
7.5 7.5 1.0 1.33 ± 0.22 96.43 
2.5 7.5 1.0 1.30 ± 0.21 96.91 
2.5 5 1.8 0.98 ± 0.62 96.21 
7.5 5 1.8 2.58 ± 1.02 97.1 
5 2.5 0.55 2.73 ± 0.38 97.28 
5 7.5 1.8 2.82 ± 0.74 96.98 
2.5 2.5 1.0 0.70 ± 0.36 97.18 
7.5 2.5 1.0 3.78 ± 1.64 96.71 
2.5 5 0.55 2.48 ±1.49 96.39 
5 7.5 0.55 4.20 ± 0.92 97.42 
7.5 7.5 1.8 3.97 ± 1.04 96.66 
2.5 2.5 0.55 3.50 ± 0.22 97.1 
5 5 0.55 1.75 ± 0.42 97.23 
5 5 1.8 2.80 ± 1.40 96.7 
7.5 5 1.0 1.45 ± 0.44 95.79 
 
Percent drug encapsulation efficiency (PDEE) 
 
Eighteen microparticulate formulations were 
evaluated for drug encapsulation efficiency and 
the results of the PDEE is shown in Table 2. The 
range was between 95.79 – 97.42 %. This was 
above the minimum constraint on PDEE. 
 
Optimization of the batches 
 
Based on the constraints imposed on particle 
size and percent drug encapsulation efficiency, 
three formulations were selected and evaluated. 
The results are shown in Table 3. 
 
Table 3: Optimized batches and their correspondent 










F1 7.5:2.5:0.55 96.29 1.1 ± 
0.62 
F2 2:2.5:1.8 96.29 0.98 ± 
0.62 
F3 2:2:1.0 97.18 0.70 ± 
0.36 
Key: aC:A:C = chitosan:alginate:calcium chloride; 
bPDEE = percent drug encapsulation efficiency; cPS = 
particle size 
  
Determination of mucoadhesion of 
microparticles on hog everted tissue 
 
The mucoadhesion of the microparticles in SIF 
(pH 7.2) and SGF (pH 1.2) are presented in 
Table 4. The result showed higher 
mucoadhesion in SIF. F1 had the highest 
mucoadhesion of 76 % to the everted hog tissue 
while F2 and F3 were 60 % which was equally 
high. In SGF, the mucoadhesion was very low 
with F1, F2 and F3 having mucoadhesion from 
32-36 %.  
 
Table 4: Mucoadhesion of the microparticles ex vivo in 





in SIF (%) 
Mucoadhesion 
in SGF (%) 
F1 76 36 
F2 60 32 
F3 60 32 
 
In vitro drug release  
 
The release profiles of different formulations (F1 
to F3) are shown in Figures 1a and b. In SIF for a 
maximum of 24 h, a cumulative of 21.28 %, 
30.89 % and 38.85 % of amoxicillin were 
released from F1, F2 and F3 respectively while 
28.28 %, 37.25 % and 44.59 % of amoxicillin 
were released from F1, F2 and F3 respectively in 
SGF. 
 
Drug release kinetics 
 
It can be seen from Tables 5 and 6 that the 
coefficient of determination (r2) is highest in the 
Higuchi model in both SIF and SGF and in all the 
formulations. The highest was 0.94 and this 
means that 94 % variability in the response will 
be explained by the model. The drug release 
data was fitted to the well-known exponential 
equation (Korsmeyer-Peppas equation) which is 
often used to describe the drug release behavior 
from polymeric systems. From Table 5, F1 to F3 
had n-values higher than 1 in SIF while F1 to F3 
had values between 0.94 and 1.09 in SGF. 
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Figure 1: Release profile of coated chitosan microparticles in (a) SIF and (b) SGF. Key: F1 = dotted line; F2 = 
dashed line; F3 = unbroken line 
 







First order Higuchi Model Korsemeyer-
Peppas 
r2               K0 r2                 K1 r2 KH r2 n 
SIF 
F1 0.77 0.87 0.75 -0.004 0.91 4.66 0.82 1.32 
F2 0.80 1.49 0.74 -0.006 0.90 7.18 0.87 1.38 
F3 0.85 1.81 0.80 -0.008 0.93 8.69 0.91 1.41 
SGF 
F1 0.88 0.87 0.79 -0.004 0.92 4.99 0.85 0.94 
F2 0.80 1.49 0.82 -0.008 0.94 8.54 0.87 1.06 
F3 0.85 1.81 0.86 -0.010 0.92 9.95 0.87 1.09 
 
Susceptibility of microorganisms to alginate-
coated amoxicillin-loaded microparticles 
 
Figure 2 shows that Staphylococcus aureus was 
most susceptible to the three optimized 
formulations as well as the marketed amoxicillin 
tablet. The highest IZD of 53.66 ± 1.53 mm was 
produced by F1 against Staphylococcus aureus. 
 
When the formulations were compared with the 
commercial amoxicillin, there was no significant 
difference at p < 0.05 in the inhibition zone 
diameters against E. coli. There were some 
significant differences between F2, F3 and the 
commercial amoxicillin against Salmonella typhi. 
There were also significant differences between 
F1, F2 and the commercial amoxicillin against 
Staphylococcus aureus. There were significant 
differences in the inhibitions of formulations F1, 
F2 and F3 on S. typhi in this order: F2 > F3 >F1. 
There was no significant difference in the 
activities of the three formulations on E. coli as 
seen in Table 6.  
 
 
Figure 2: Inhibition zone diameters of the optimized batches against the isolates. Colour code: Green = E.coli; 
blue = S. typhi; orange = S. aureus 
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Table 6: Statistical data on antibacterial activity of the formulation on clinical isolates 
 
Formulation E. coli Salmonella typhi S. aureus. 
F1 and Standard 0.074 0.29 0.000021* 
F2 and Standard 1 0.00022* 0.0065* 
F3 and Standard 0.9 0.0023* 0.374 
F1 and F2 0.074 0.00167* 0.24 
F1 and F3 0.345 0.01* 0.14 
F2 and F3 0.900 0.03* 0.32 




The particles ranged from 0.70 to 5.25 µm. The 
distribution of the sizes was varied. There was no 
significant correlation between the different ratios 
of the independent variables and particle size 
though there was an occurrence of low 
concentration of chitosan and small sizes of the 
microparticles. The size range is appropriate for 
oral delivery and uptake. 
 
The high encapsulation of amoxicillin drug shows 
a strong affinity of the drug for the biopolymer 
and a good absorption enhancing effect of the 
microparticles [9]. A drug associates with 
chitosan through hydrophobic interactions or 
electrostatic interactions or hydrogen bonding. 
The coating of alginate which is hydrophilic 
would also greatly increase circulation time of the 
microparticles in the system [9]. Alginate coating 
would also prevent rapid degradation of the 
amoxicillin in the gastric fluid if delivered orally. It 
is essential in drug delivery to determine the 
encapsulation efficiency of a carrier because its 
efficacy depends strongly on it [10]. Adhesive 
properties of mucoadhesive polymers are 
generally affected by their swelling behavior. 
Mucoadhesive microparticles take up water from 
the underlying mucosal tissue by absorption, 
swelling, capillary effects and uncoiling of 
polymer chains leading to considerably stronger 
adhesion [11]. The alginate-coated chitosan 
microparticles had a strong adhesion to the ileum 
in SIF but was eroded in the presence of SGF 
due to poor hydration and swelling of the polymer 
in the acidic environment leading to low 
adhesion. There may also be poor interaction of 
the alginate with the sialic acid and other anionic 
groups present on the mucin [3]. 
 
The slow release of amoxicillin from the 
microparticles may be due to high viscosity of the 
alginate gels or strong affinity of the drug to the 
chitosan particles which resulted in hindered 
migration of amoxicillin molecules in the 
dissolution medium. Alginate gels have also 
been utilized to form a matrix in which depots 
releasing small drugs can be incorporated, for 
example, amoxicillin-loaded Chitosan/poly(γ-
glutamic acid) nanoparticles have been 
incorporated into alginate/calcium ions hydrogels 
for effective treatment of Helicobacter pylori 
infection. The alginate gel outer layer protected 
the amoxicillin-loaded nanoparticles in the gastric 
environment, and facilitated amoxicillin 
interactions specifically with intercellular spaces, 
which is the infection site of H. pylori [12]. When 
a microparticle is brought into contact with a 
liquid medium, the solvent diffuses into the 
polymer, causing it to swell. pH and cross-linking 
also control the rate of swelling. Diffusion occurs 
which involves migration of water into pre-
existing or dynamically formed spaces between 
hydrogel chains [12]. The n-values of the 
diffusion of amoxicillin through the alginate-
coated polymer was between 0.94 and 1.09 
showing mostly non-fickian diffusion mechanism 
meaning that the diffusion and relaxation rates 
were comparable. The result of the sensitivity 
studies which was done under similar conditions 
showed that there was no reduction in potency or 
stability of the amoxicillin encapsulated in 
alginate-coated chitosan microparticles by 




Alginate-coated chitosan microparticles hold 
good prospects for amoxicillin drug delivery for 
gastric ulcer therapy. It is biodegradable, 
biocompatible and mucoadhesive. The ionotropic 
gelation technique produced particles with 
suitable mean size and high encapsulation 
efficiency. Drug release is sustained and 
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